Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia

被引:0
作者
Rubeen Israni
Keith A. Betts
Fan Mu
Jill Davis
Jessie Wang
Deborah Anzalone
Gabriel I. Uwaifo
Harold Szerlip
Vivian Fonseca
Eric Wu
机构
[1] AstraZeneca,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Ochsner Medical Center,undefined
[5] Baylor University Medical Center,undefined
[6] Tulane University Health Sciences Center,undefined
来源
Advances in Therapy | 2021年 / 38卷
关键词
Hyperkalemia; Chronic kidney disease; Comorbidities; Real-world evidence;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:5596 / 5608
页数:12
相关论文
共 87 条
[1]  
Gumz ML(2015)An integrated view of potassium homeostasis N Engl J Med 373 60-72
[2]  
Rabinowitz L(2012)Predictors of hyperkalemia and death in patients with cardiac and renal disease Am J Cardiol 109 1510-1513
[3]  
Wingo CS(2011)Pathogenesis, diagnosis and management of hyperkalemia Pediatr Nephrol 26 377-384
[4]  
Jain N(2018)The prevalence of hyperkalemia in the United States Curr Med Res Opin 34 971-978
[5]  
Kotla S(2010)Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors Clin J Am Soc Nephrol 5 531-548
[6]  
Little BB(2009)Hyperkalaemia BMJ 339 b4114-58
[7]  
Lehnhardt A(2019)Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome Int J Cardiol 274 52-393
[8]  
Kemper MJ(2019)Hyperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients J Am Heart Assoc 8 e011814-3165
[9]  
Betts KA(2018)The cost of hyperkalemia in the United States Kidney Int Rep 3 385-591
[10]  
Woolley JM(2017)How dangerous is hyperkalemia? J Am Soc Nephrol 28 3155-516